Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial

被引：0
|
作者：
Harrison, Stephen
Alkhouri, Naim [1 ]
Taub, Rebecca [2 ]
Neff, Guy [3 ]
Baum, Seth J. [4 ]
Younes, Ziad H. [5 ]
Bashir, Mustafa [6 ]
机构：
[1] Arizona Liver Hlth, Phoenix, AZ USA
[2] Madrigal Pharmaceut, Res, Conshohcken, PA USA
[3] Covenant Res LLC, Sarasota, FL USA
[4] Excel Med Clin Trials LLC, Miami, FL USA
[5] Gastro One, Memphis, TN USA
[6] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27706 USA
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
GS-2563
引用
收藏
页码：S200 / S200
页数：1
相关论文
共 50 条
  • [1] A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis Reply
    Sabet, Amin
    Harrison, Stephen A.
    Taub, Rebecca
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (17): : 1632 - 1633
  • [2] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
    Harrison, Stephen A.
    Bedossa, Pierre
    Guy, Cynthia D.
    Schattenberg, Joern M.
    Loomba, Rohit
    Taub, Rebecca
    Labriola, Dominic
    Moussa, Sam E.
    Neff, Guy W.
    Rinella, Mary E.
    Anstee, Quentin M.
    Abdelmalek, Manal F.
    Younossi, Zobair
    Baum, Seth J.
    Francque, Sven
    Charlton, Michael R.
    Newsome, Philip N.
    Lanthier, Nicolas
    Schiefke, Ingolf
    Mangia, Alessandra
    Pericas, Juan M.
    Patil, Rashmee
    Sanyal, Arun J.
    Noureddin, Mazen
    Bansal, Meena B.
    Alkhouri, Naim
    Castera, Laurent
    Rudraraju, Madhavi
    Ratziu, Vlad
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (06): : 497 - 509
  • [3] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
    Hong, Hyeyeon
    Choi, Jonggi
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (06): : 253 - 255
  • [4] RESMETIROM IMPROVES THE ATHEROGENIC LIPID/LIPOPROTEIN PROFILE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL
    Alkhouri, Naim
    Bedossa, Pierre
    Guy, Cynthia D.
    Schattenberg, Joern M.
    Loomba, Rohit
    Taub, Rebecca A.
    Labriola, Dominic
    Moussa, Sam
    Neff, Guy W.
    Sanyal, Arun
    Noureddin, Mazen
    Bansal, Meena B.
    Ratziu, Vlad
    Harrison, Stephen A.
    HEPATOLOGY, 2023, 78 : S1207 - S1213
  • [5] A 52-WEEK PHASE 3 CLINICAL TRIAL OF RESMETIROM IN 180 PATIENTS WITH WELL-COMPENSATED NASH CIRRHOSIS
    Harrison, Stephen A.
    Alkhouri, Naim
    Taub, Rebecca A.
    Neff, Guy W.
    Kowdley, Kris V.
    Noureddin, Mazen
    HEPATOLOGY, 2022, 76 : S90 - S92
  • [6] BIOMARKERS, IMAGING AND SAFETY IN RESMETIROM 52 WEEK NON-CIRRHOTIC NASH PHASE 3 CLINICAL TRIAL, COMPLETED OPEN-LABEL ARM OF MAESTRO-NAFLD-1
    Harrison, Stephen A.
    Cubberley, Sarah
    Taub, Rebecca A.
    Neff, Guy W.
    Alkhouri, Naim
    Bashir, Mustafa
    HEPATOLOGY, 2021, 74 (06) : 1403A - 1403A
  • [7] Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy study
    Anstee, Quentin M.
    Schattenberg, Jorn M.
    Taub, Rebecca
    Labriola, Dominic
    Zhang, Hang
    Hennan, Jim
    JOURNAL OF HEPATOLOGY, 2024, 80 : S509 - S509
  • [8] ALGORITHM FOR PREDICTING ADVANCED NASH FIBROSIS ON SCREENING BIOPSY IN RESMETIROM PHASE 3 MAESTRO-NASH CLINICAL TRIAL
    Harrison, Stephen A.
    Taub, Rebecca A.
    Karsdal, Morten Asser
    France, John
    Bashir, Mustafa
    Barbone, Jordan Mark
    Neff, Guy
    Gunn, Nadege T.
    Moussa, Sam
    HEPATOLOGY, 2020, 72 : 1008 - 1009
  • [9] RESMETIROM TREATMENT HELPS RESTORE THYROID HORMONE LEVELS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRONASH TRIAL
    Harrison, Stephen A.
    Bedossa, Pierre
    Guy, Cynthia D.
    Schattenberg, Joern M.
    Loomba, Rohit
    Taub, Rebecca A.
    Labriola, Dominic
    Moussa, Sam
    Neff, Guy W.
    Sanyal, Arun
    Noureddin, Mazen
    Bansal, Meena B.
    Alkhouri, Naim
    Ratziu, Vlad
    HEPATOLOGY, 2023, 78 : S1213 - S1219
  • [10] RELATIONSHIP OF NON-INVASIVE MEASURES WITH HISTOLOGICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL
    Loomba, Rohit
    Schattenberg, Joern M.
    Taub, Rebecca A.
    Labriola, Dominic
    Noureddin, Mazen
    Ratziu, Vlad
    Harrison, Stephen A.
    HEPATOLOGY, 2023, 78 : S155 - S159
12345